Intellia To Test Second CRISPR Therapeutic In Hereditary Angioedema Patients

  • The New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE) has signed off Intellia Therapeutics Inc's NTLA Phase 1/2 study of NTLA-2002 in hereditary angioedema (HAE).
  • NTLA-2002 is a systemically administered single-dose CRISPR / Cas9-based therapeutic candidate designed to inactivate the target gene Kallikrein B1 (KLKB1) to reduce plasma kallikrein activity and thus prevent HAE attacks.
  • The NTLA-2002 program represents the second systemic in vivo CRISPR genome editing therapy candidate to enter human clinical trials.
  • Related: Intellia Shares Promising Biomarker Data From CRISPR/Cas9 Genome Editing Candidate.
  • The Phase 1/2 study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of NTLA-2002 in adult patients.
  • The Phase 1 portion of the study is an open-label, single-ascending dose design used to identify up to two dose levels of NTLA-2002 that will be further evaluated in the randomized, placebo-controlled Phase 2 portion of the study. 
  • Beyond New Zealand, Intellia is submitting additional regulatory applications in other countries as part of its ongoing, multi-national development approach for NTLA-2002.
  • Related: Intellia To Test CRISPR-Engineered TCR-T Cell Candidate In Acute Myeloid Leukemia Patients.
  • Price Action: NTLA stock is up 0.57% at $130.5 during the premarket session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareFDAGeneralBriefsGene Editinghereditary angioedemaPhase 1 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!